(Q37417765)

20 August 2017

1 reference

title

A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout (English)

1 reference

20 August 2017

1 reference

Jeannie Chao

1

1 reference

PubMed ID

19296886

20 August 2017

Robert Terkeltaub

series ordinal

2

1 reference

PubMed ID

19296886

20 August 2017

language of work or name

1 reference

1 April 2009

1 reference

Current Rheumatology Reports

20 August 2017

1 reference

20 August 2017

11

1 reference

20 August 2017

2

1 reference

20 August 2017

135-140

1 reference

https://scigraph.springernature.com/pub.10.1007/s11926-009-0019-z

20 August 2017

0 references

cites work

Allopurinol hepatotoxicity. Report of two cases and review of the literature

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11926-009-0019-Z

Allopurinol hepatotoxicity. Case report and literature review

21 January 2018

1 reference

12 December 2020

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

1 reference

12 December 2020

Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease

1 reference

12 December 2020

British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout

1 reference

12 December 2020

Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?

1 reference

12 December 2020

Gout management: let's get it right this time

1 reference

12 December 2020

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout

1 reference

12 December 2020

Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout

1 reference

12 December 2020

Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study

1 reference

12 December 2020

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial

1 reference

12 December 2020

Treatment-failure gout: a moving target

1 reference

12 December 2020

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

1 reference

12 December 2020

Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts

1 reference

12 December 2020

Gout medication treatment patterns and adherence to standards of care from a managed care perspective

1 reference

12 December 2020

Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity

1 reference

12 December 2020

Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events

1 reference

12 December 2020

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

1 reference

12 December 2020

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

1 reference

12 December 2020

A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout

1 reference

12 December 2020

Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?

1 reference

12 December 2020

Uric acid and cardiovascular risk

1 reference

12 December 2020

Gout: on the brink of novel therapeutic options for an ancient disease

1 reference

12 December 2020

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

1 reference

12 December 2020

Relation between adverse events associated with allopurinol and renal function in patients with gout

1 reference

12 December 2020

Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol

1 reference

12 December 2020

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

1 reference

12 December 2020

Cell-mediated immunity in allopurinol-induced hypersensitivity

1 reference

12 December 2020

Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial

1 reference

12 December 2020

Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice

1 reference

12 December 2020

Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?

1 reference

12 December 2020

Allopurinol hepatotoxicity

1 reference

12 December 2020

10.1007/S11926-009-0019-Z

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19296886